Form 8-K - Current report:
SEC Accession No. 0001104659-21-140046
Filing Date
2021-11-16
Accepted
2021-11-16 17:07:38
Documents
16
Period of Report
2021-11-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2133167d1_8k.htm   iXBRL 8-K 35721
2 EXHIBIT 10.1 tm2133167d1_ex10-1.htm EX-10.1 56378
3 EXHIBIT 10.2 tm2133167d1_ex10-2.htm EX-10.2 37113
4 EXHIBIT 10.3 tm2133167d1_ex10-3.htm EX-10.3 29679
  Complete submission text file 0001104659-21-140046.txt   418440

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA otlk-20211116.xsd EX-101.SCH 3552
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE otlk-20211116_def.xml EX-101.DEF 26932
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20211116_lab.xml EX-101.LAB 36890
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20211116_pre.xml EX-101.PRE 25550
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2133167d1_8k_htm.xml XML 5428
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 211417179
SIC: 2836 Biological Products, (No Diagnostic Substances)